PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $456 | -23.4% | 14,868 | 0.0% | 0.01% | -16.7% |
| Q2 2023 | $595 | +3.7% | 14,868 | +5.7% | 0.01% | 0.0% |
| Q1 2023 | $574 | -52.9% | 14,063 | -55.5% | 0.01% | -53.8% |
| Q4 2022 | $1,219 | -99.9% | 31,574 | +3.7% | 0.01% | -31.6% |
| Q3 2022 | $1,619,000 | -23.2% | 30,439 | +10.2% | 0.02% | -9.5% |
| Q1 2022 | $2,107,000 | +189.4% | 27,616 | +128.2% | 0.02% | +250.0% |
| Q4 2021 | $728,000 | +7.4% | 12,100 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $678,000 | -7.6% | 12,100 | 0.0% | 0.01% | -14.3% |
| Q2 2021 | $734,000 | -13.4% | 12,100 | 0.0% | 0.01% | -12.5% |
| Q1 2021 | $848,000 | +17.1% | 12,100 | 0.0% | 0.01% | +14.3% |
| Q4 2020 | $724,000 | -0.4% | 12,100 | 0.0% | 0.01% | -12.5% |
| Q3 2020 | $727,000 | +14.5% | 12,100 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $635,000 | +56.4% | 12,100 | 0.0% | 0.01% | +33.3% |
| Q1 2020 | $406,000 | -29.4% | 12,100 | -4.7% | 0.01% | 0.0% |
| Q4 2019 | $575,000 | – | 12,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |